9-Chloro-2-ethyl-6-methyl-3-(2,2,2-trifluoroethyl)pyrrolo[3,2-f]quinolin-7-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 9-Chloro-2-ethyl-6-methyl-3-(2,2,2-trifluoroethyl)pyrrolo[3,2-f]quinolin-7-one
• 英文别名: 9-chloro-2-ethyl-6-methyl-3-(2,2,2-trifluoroethyl)pyrrolo[3,2-f]quinolin-7-one
• 化学式: C₁₆H₁₄ClF₃N₂O
• 分子量: 342.74
• InChiKey: HZPAIMQZZGEGBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  25.2
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSÉS ET COMPOSITIONS UTILISÉS POUR TRAITER LES MALADIES NEURODÉGÉNÉRATIVES
  申请人：ACADIA PHARM INC

  公开号：WO2014125121A1

  公开（公告）日：2014-08-21

  The present application relates to a composition comprising a selective androgen modulating compound of formula (I) and selective estrogen receptor β agonist of formula (II). The present application also relates to the use of a selective androgen modulating compound of formula (I) in combination with a selective estrogen receptor β agonist of formula (II) in the treatment or prevention of neurodegenerative diseases or disorders,such as Alzheimer's disease, Huntigton's disease, Parkinson's disease, depression, anxiety, multiple sclerosis, symptoms associated with or caused by multiple sclerosis, and acute or chronic pain.

  本申请涉及一种包含公式（I）的选择性雄激素调节化合物和公式（II）的选择性雌激素受体β激动剂的组合物。本申请还涉及将公式（I）的选择性雄激素调节化合物与公式（II）的选择性雌激素受体β激动剂结合使用，用于治疗或预防神经退行性疾病或障碍，例如阿尔茨海默病、亨廷顿病、帕金森病、抑郁症、焦虑症、多发性硬化症、与多发性硬化症相关或由其引起的症状，以及急性或慢性疼痛。
• METHODS OF REDUCING MAMMOGRAPHIC BREAST DENSITY AND/OR BREAST CANCER RISK
  申请人：Havah Therapeutics Pty Ltd

  公开号：EP3209301A1

  公开（公告）日：2017-08-30
• [EN] DRUG COMBINATIONS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND METHODS OF MAKING AND USING THEM<br/>[FR] COMBINAISONS DE MÉDICAMENTS AVEC DES MODULATEURS DE RÉCEPTEUR D'ANDROGÈNE SÉLECTIFS (SARM), ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：VICUS THERAPEUTICS LLC

  公开号：WO2016061135A1

  公开（公告）日：2016-04-21

  In alternative embodiments, provided are therapeutic combinations, pharmaceutical compositions, formulations, kits and devices comprising drug combinations including a selective androgen receptor modulator (SARM), e.g., such as enobosarm or andarine, with one or more additional drugs or active agents, and methods for making and using them for treating, ameliorating, reversing or preventing a cancer such as a breast cancer, a basal-like carcinoma, a ductal carcinoma or an ovarian cancer, a tumor, a burn or a short stature or related syndrome or condition.
• [EN] METHODS OF REDUCING MAMMOGRAPHIC BREAST DENSITY AND/OR BREAST CANCER RISK<br/>[FR] PROCÉDÉS DE RÉDUCTION DE LA DENSITÉ MAMMAIRE À LA MAMMOGRAPHIE ET/OU DU RISQUE DE CANCER DU SEIN
  申请人：HAVAH THERAPEUTICS PTY LTD

  公开号：WO2017066827A1

  公开（公告）日：2017-04-27

  The present disclosure is directed to generally methods and/or compositions for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a pre- menopausal, a peri-menopausal or a post-memopausal patient, comprising the admimstration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. The present disclosure is also directed to methods and/or compositions for reducing breast pain. The present disclosure is also directed to method and/or compositions for reduing elasticity and/or decreasing mechano -transduction on the genome of breast cells. The present disclosure is also directed to methods and/or compositions for stabilizing and/or increasing the levels of androgen receptor expression in breast tissue.